| JnJ–Valneva: investment, 201502 acquisition €45m of Crucell Sweden AB + affiliates incl all assets related to Dukoral |
2015-02-10 |
| Signature Diagnostics–Roche: investment, 201502 acquisition of SDx by Roche |
2015-02-09 |
| Exquiron Biotech–SAMDI Tech: drug discovery services, 201502– collab mutually co-promotion of respective services in Europe + North America |
2015-02-08 |
| Advanced Scientifics–Thermo Fisher: investment, 201502 acquisition $300m in cash |
2015-02-05 |
| Nanion–Ratos: patch clamp technology, 201502– license non-excl to key patent providing freedom-to-operate for life time of patent from Biolin |
2015-02-05 |
| SciLifeLab (SE)–Fluidigm: CyTOF mass cytometer, 201502 supply three CyTOF 2 systems to Swedish National Center for Single-Cell Analysis |
2015-02-05 |
| Zedira–Germany (govt): grant, 201502– BMBF funding €1m to support further coagulation factor XIIIa inihibitor development |
2015-02-03 |
| Zedira–Univ Marburg: structural biology, 201502 collab existent w group of Prof Gerhard Klebe |
2015-02-03 |
| Poonawalla–Genticel: vaccine technology, 201502– license to Vaxiclase platform for pertussis vaccine $57m upfront + milestones + royalties to SII |
2015-02-02 |
| R2R Biofluidics project–EU (govt): grant, 201502–201901 H2020 grant €6.4m out of total budget of €7.9m |
2015-02-01 |
| Atlas Genetics–Bellevue: investment, 201501 financing round Series C totalling $20m incl returning investor BB Biotech Ventures |
2015-01-29 |
| Atlas Genetics–Novartis: investment, 201501 financing round Series C totalling $20m incl returning investor Novartis Venture Funds |
2015-01-29 |
| Atlas Genetics–Russia (govt): investment, 201501 financing round Series C totalling $20m incl new investor RMI Partners |
2015-01-29 |
| Atlas Genetics–SEVERAL: investment, 201501 financing round Series C $20m from existing investors + new investor RMI Partners |
2015-01-29 |
| Nanocomp–Evonik: investment, 201501– strategic minority investment €na by Evonik Venture Capital |
2015-01-29 |
| Oncgnostics–High-Tech Gründerfonds: investment, 201501 financing round Series A totalling € 7-digit incl existing investor HTGF |
2015-01-29 |
| Oncgnostics–SEVERAL: investment, 201501 financing round Series A € 7-digit led by new investor bm|t |
2015-01-29 |
| Fodjan–High-Tech Gründerfonds: investment, 201501 seed investment € 6-digit by HTGF |
2015-01-28 |
| Ratos–Xention: patch clamp technology, 201501 acquisition key patent by Biolin Scientifc from Xention Ltd |
2015-01-27 |
| Dacheng–Dentons: investment, 201501– merger signed to become largest law firm ww |
2015-01-26 |
| Nanion–Tokyo Women’s Medical Univ: patch clamp system, 201501– collab optimising performance of iPS cells an Nanion systems |
2015-01-22 |
| Sigma-Aldrich–VIB: research reagents, 201501– alliance to provide products + tools + technologies for translational research |
2015-01-22 |
| BioNova Cientifica–Genetrix (ES): nucleic acid amplification technology, 201501– distribution of Sygnis TruePrime Single Cell WGA kit in Spain |
2015-01-21 |
| InnoCyte–PharmaCell: cell analysis technology, 201501– collab within Biomat-IN network to scientifically support split.it cell passage device |
2015-01-21 |
| Trophos–Roche: investment, 201501 acquisition €120m upfront cash + €350m milestones |
2015-01-16 |
| ASPEC Technologies–CovalX: mass spectrometry, 201501 collab existent ASPEC is distributor of CovalX High-Mass systems in China |
2015-01-15 |
| Sanofi–Boehringer: biologics contract manufacturing, 201501– supply strategic manufacturing alliance to supply therapeutic ABs to Sanofi |
2015-01-15 |
| Roche–Human Longevity: genome sequencing services, 201501– supply €na multi-year agreem with Genentech for whole genome sequencing + data analysis |
2015-01-14 |
| Boehringer–Vanderbilt Univ: Ras inhibitors, 201501– collab multi-year €na r+d small-molecule Ras inhibitors for cancer |
2015-01-13 |
| Boehringer–Vanderbilt Univ: Ras inhibitors, 201703– collab expansion r+d small-molecule KRAS inhibitors for cancer |
2015-01-13 |
| Boehringer–Yale Univ: immunotherapy, 201501– collab identification of targets + agents w excl licensing option for BI |
2015-01-13 |
| Cortendo–SEVERAL: investment, 201501 private placement $27.5m (SEK221m) incl RA Capital + NEA + Broadfin Capital + HealthCap |
2015-01-13 |
| GenePOC–Debiopharm: investment, 201501 financing round led by Debiopharm Diagnostics + Emerillon Capital |
2015-01-13 |
| GenePOC–SEVERAL: investment, 201501 financing round led by Debiopharm Diagnostics + Emerillon Capital |
2015-01-13 |
| Artel–Stratec: liquid handling technology, 201501– distribution excl marketing of Tholos liquid handling quality assurance instrumentation solution |
2015-01-12 |
| Foundation Medicine–Roche: investment, 201501– acquisition majority share up to 56.3% via $780m tender offer + $250m new shares $50/share |
2015-01-12 |
| JnJ–AC Immune: therapeutic vaccines, 201501– collab + license up to $509m (CHF500m) ACI-35 + 3y research therap vaccines for tauopathies |
2015-01-12 |
| Valneva–SEVERAL: investment, 201501–201502 capital increase €45m 18.23m new ordinary shares to finance acquisition of Crucell Sweden AB |
2015-01-12 |
| Qiagen–ArcherDX: DNA sequencing technology, 201501– distribution €na of Archer NGS products by Qiagen |
2015-01-11 |
| Agenus–Incyte: investment, 201501 equity investment $35m at $4.51/share by Incyte as part of ww cancer immunotherapy alliance |
2015-01-09 |
| Incyte–Agenus: cancer immunotherapy, 201501– collab ww alliance $25m upfront + $350m milestones + $35m equity investment using Retrocyte Display techn |
2015-01-09 |
| Haplogen–Horizon Discovery: investment, 201501 acquisition of Haplogen Genomics GmbH for upfront €3.8m cash + €3.8m shares + €5m milestones in shares |
2015-01-08 |
| Miracor–SEVERAL: investment, 201501 financing round Series B extension €4.5m from BioMedInvest + AWS + SHS + Earlybird + Delta Partners |
2015-01-08 |
| Addex–United States (govt): ADX71441, 201501– collab NIAAA to evaluate ADX71441 in preclinical models of alcohol use disorder |
2015-01-07 |
| Affimed–Germany (govt): grant, 201501– BMBF grant €2.4m to develop Trispecfic ABs within KMUinnovative BioChance program |
2015-01-07 |
| Affimed–MacDougall Biomedical Communications: public relations, 201501 service existent by MacDougall Munich Office |
2015-01-07 |
| Caribou Biosciences–Novartis: investment, 201501 equity investment by Novartis in connection w collab + license agreement |
2015-01-07 |
| Close Brothers–Oddo: investment, 201501 acquisition of Close Brothers Seydler Bank AG by Oddo & Cie |
2015-01-07 |
| Genkyotex–SEVERAL: investment, 201501 financing round Series D CHF20m=$21m led by new investor NeoMed Management |
2015-01-07 |
| Intellia Therapeutics–Novartis: investment, 201501 increase of equity investment by Novartis |
2015-01-07 |
| Novartis–Caribou Biosciences: CRISPR technology, 201501– collab + license agreem non-excl for devlopm of drug discovery tools |
2015-01-07 |
| Novartis–Intellia Therapeutics: CRISPR technology, 201501– collab + license agreem incl upfront paym + investm + funding + milestones + royalties |
2015-01-07 |
| Gilead–Phenex: FXR agonists, 201501 acquisition of Phenex’ FXR agonists program for NASH + other liver diseases for up to $470m |
2015-01-06 |
| OnCore BioPharma–Cytos Biotechnology: VLP technology, 201501– license to OnCore excl for use of VLP platform in treatm + prevention of HBV infections |
2015-01-06 |
| Provendis–TVM: venture capital, 201501– collab support in project evaluation + financing by TVM Capital Life Science for projects of Provendis |
2015-01-06 |
| Boehringer–BioMed X: pharma research, 201501– collab new BioMed X research group to discover new epigenetic COPD regulators |
2015-01-05 |
| Redbiotec–Pfizer: investment, 201501 acquisition of controlling interest in Redvax GmbH, a spin-off from Redbiotec AG |
2015-01-05 |
| Aevotis–Evocatal: investment, 201501 acquisition €na of majority stake by Evocatal |
2015-01-01 |
| Atomwise–SEVERAL: investment, 2015 seed financing round incl Y Combinator + Khosla Ventures + DJF |
2015-01-01 |
| Bayer–Proteros: drug discovery services, 201501–201612 collab identification of cardiovascular compounds for integral membrane protein |
2015-01-01 |
| Biocentric–Hain Lifescience: investment, 2015 acquisition of Biocentric by Hain |
2015-01-01 |
| EffRx–SEVERAL: investment, 201501 financing round CHF2.3m from existing investors |
2015-01-01 |
| GreenBone–SEVERAL: investment, 2015 seed financing round €3m from ZernikeMeta Ventures + Italian Angels for Growth + private investors |
2015-01-01 |
| IFM Therapeutics–Atlas Venture: investment, 2015 seed funding by Atlas Venture |
2015-01-01 |
| Jecure Therapeutics–Versant Ventures: investment, 2015 seed financing from founding investor Versant Ventures |
2015-01-01 |
| KBI BioPharma–JSR Corp: investment, 2015 acquisition of KBI BioPharma Inc by JSR Corp |
2015-01-01 |
| Mérieux–Copan: sample prep automation, 201501– collab distribution of WASP + WASPLab systems by bioMérieux starting in FR+DE+UK + to be expanded |
2015-01-01 |
| Novartis–Fraunhofer: cell therapy production, 201501– collab developm of production capacity for Kymriah in Europe at Fraunhofer IZI |
2015-01-01 |
| Novartis–Fraunhofer: cell therapy production, 201808– service supply production of Kymriah in Europe by Fraunhofer IZI |
2015-01-01 |
| Numares–SHS: investment, 2015 existent SHS Gesellschaft für Beteiligungsmanagement is main shareholder |
2015-01-01 |
| Oncgnostics–MDxHealth: PCR technology, 201501– license ww non-excl for MSP technology for cervical cancer diagnostics to Oncgnostics |
2015-01-01 |
| Padlock Therapeutics–Evotec: drug discovery services, 201501–201703 extension of collab to deliver multiple PAD inhibitor development candidates |
2015-01-01 |
| ProteoMedix–SEVERAL: investment, 201501 2nd closing of financing round Series B CHF1m bringing total round to CHF4.2m |
2015-01-01 |
| Roche–4D Molecular Therapeutics: gene delivery technology, 2015– collab research |
2015-01-01 |
| Seres Therapeutics–Nestlé: investment, 201501 equity investment by Nestlé Health Science |
2015-01-01 |
| VIB–Lipotype: mass spectrometry services, 2015– collab supply of shotgun lipidomics services by Lipotype to researchers at VIB |
2015-01-01 |
| ViraTherapeutics–Austria (govt): investment, 2015c financing €1.6m from FFG + aws seed financing programme |
2015-01-01 |
| Enzymatics–Qiagen: investment, 201412 acquisition €na of all assets of Enzyme Solution Unit of Enzymatics by Qiagen |
2014-12-31 |
| RiNA GmbH–NONE: investment, 201412–201506 bankruptcy AG Berlin-Charlottenburg 36R IN 4968/14 Massenunzulänglichkeit |
2014-12-29 |
| Pieris–SEVERAL: investment, 201412 private placement $13.56m with 6.8m shares common stock $2/share |
2014-12-23 |
| Pieris–Trout Group: public relations, 201412 service existent |
2014-12-23 |
| Bina Technologies–Roche: investment, 201412 acquisition of Bina by Roche |
2014-12-19 |
| Dutalys–Roche: investment, 201412 acquisition $133.75m upfront cash + $355m milestones |
2014-12-18 |
| OncoEthix–Merck (US): investment, 201412 acquisition $110m upfront + $265m milestones by Merck through a subsidiary |
2014-12-18 |
| Pieris–Ally Bridge Group: investment, 201412 private placement totalling $13.56m incl investor ABG |
2014-12-18 |
| Pieris–Marika: investment, 201412 reverse merger to list Pieris AG in US with Marika Inc renamed Pieris Pharmaceuticals Inc |
2014-12-18 |
| Emergent BioSolutions–Evolva: antibiotics, 201412 acquisition EV-035 series of broad spectrum antibiotics incl GC-072 for up to $70.5m plus royalties |
2014-12-17 |
| Humedics–BioMedPartners: investment, 201412 BioMedInvest-II LP fund joins Series C w approx €700k bringing round to €7m |
2014-12-17 |
| MeVis–Varian Medical Systems: investment, 201412–201504 public cash tender offer €30m with €17.5/share |
2014-12-17 |
| Sigma-Aldrich–Indi Molecular: PCC technology, 201412– collab €na to explore use of PCC technology w Sigma-Adrich’s biological tools |
2014-12-17 |
| Protagen–Qiagen: investment, 201412 financing round 1st closing of total volume €10m incl new investor Qiagen NV |
2014-12-16 |
| Protagen–SEVERAL: investment, 201412 financing round 1st closing of total volume €10m with Qiagen + MIG Fonds + NRW.Bank + management |
2014-12-16 |
| Annexon Biosciences–Clarus Ventures: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Clarus Ventures |
2014-12-15 |
| Annexon Biosciences–Novartis: investment, 201412 financing round Series A-1 totaliing $34m incl lead investor NVF |
2014-12-15 |
| Annexon Biosciences–Satter Investment Management: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Satter |
2014-12-15 |
| Annexon Biosciences–SEVERAL: investment, 201412 financing round Series A-1 $34m led by NVF + incl Satter Investment + Clarus Ventures |
2014-12-15 |
| Deutsche Biotech Innovativ–SEVERAL: investment, 201412 capital increase €408.9k via private placement of 34,800 new shares with €11.75/share |
2014-12-12 |
| Genetrix (ES)–SEVERAL: investment, 201412 rights offering + private placement of Sygnis AG €4.95m with 2.476m new shares €2/share |
2014-12-12 |
| Takasago–Evolva: fermentation technology, 201412– collab developm production technology for flavours + fragrances |
2014-12-11 |
| Roche–AvanSci Bio: tissue dissection technology, 201412 acquisition all microdissection technology assets incl MilliSect system by Roche Dx |
2014-12-10 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 28 29 30 ... 53 54 55 
Date![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lsus-life-sciences-usa-com.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
